Actively Recruiting
Evaluating Safety and Effects of EDG-15400 in Adults with Symptomatic Heart Failure with Preserved Ejection Fraction Using a Randomized, Placebo-Controlled Design
Led by Edgewise Therapeutics, Inc. · Updated on 2026-10-13
90
Participants Needed
28
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of different doses of EDG-15400 in adults with symptomatic heart failure with preserved ejection fraction HFpEF. This Phase 2 randomized, double-blind, placebo-controlled study aims to understand how EDG-15400 behaves in the body and its effects on heart failure symptoms. Participants receive either EDG-15400 at 25 mg or 50 mg, or a placebo, taken orally once daily. The study compares these groups over a treatment period lasting up to 20 weeks. The trial is designed to monitor side effects and drug levels in the blood during this time. Throughout the study, participants will be monitored for treatment-emergent adverse events and serious adverse events. Researchers will also measure changes in biomarkers and plasma concentrations of EDG-15400 from the start of treatment until completion. The total participation duration is up to 20 weeks, during which safety and drug effects are closely observed.
CONDITIONS
Brief Title
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
Research Team
S
Study Director: Medical Director, Edgewise Therapeutics, Inc.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here